Cleveland BioLabs (CBLI -3%) slips after saying it's received the end-of-Phase 2 meeting minutes...

|About: Cleveland BioLabs, Inc. (CBLI)|By:, SA News Editor

Cleveland BioLabs (CBLI -3%) slips after saying it's received the end-of-Phase 2 meeting minutes from the FDA, along with an advice letter which clarifies the remaining clinical study protocols for the development of its Entolimod as a radiation countermeasure. The firm says the agency is committed to moving the Entolimod program forward, but it has some requests regarding several aspects of the proposed plan for dose conversion.